

Supplementary Table S1 Baseline and clinical characteristics of patients

	N = 100
Age, median (range), y	49 (24–77)
Sex, n (%)	
Male	60 (60)
Female	40 (40)
Measurable disease at baseline, n (%)	81 (81)
Adequate baseline assessment, n (%)	92 (92)
Brain metastases at baseline, n (%)	56 (56)
Primary diagnosis, n (%)	
Adenocarcinoma ^a	54 (54)
Other NSCLC ^b	46 (46)
TNM stage, n (%)	
III	12 (12)
IV	88 (88)
Prior anticancer therapy regimens, n (%)	
1	57 (57)
> 1	43 (43)
Intent of therapy, n (%)	
Advanced/metastatic	95 (95)
Adjuvant therapy	4 (4)
Neoadjuvant therapy	1 (1)
Locoregional disease/recurrence ^c	1 (1)
Prior ALK TKI regimens, n (%)	
1	74 (74)
2	24 (24)
3	2 (2)
Prior ALK TKI regimen, n (%)	
Crizotinib	70 (70)
Ceritinib	51 (51)
Alectinib	5 (5)
Brigatinib	1 (1)
Gefitinib ^d	1 (1)
Prior radiotherapy, n (%)	33 (33)
Prior surgery, n (%)	12 (12)

Abbreviations: ALK, anaplastic lymphoma kinase; NSCLC, non-small-cell lung cancer; TKI, tyrosine kinase inhibitor.

^aIncludes primary diagnosis term of adenocarcinoma, adenocarcinoma metastatic, and lung adenocarcinoma.

^bIncludes primary diagnosis term of NSCLC, NSCLC metastatic, adenosquamous cell lung cancer, bronchial carcinoma, and large cell lung cancer.

^cPatient received treatment for locoregional disease/recurrence prior to being treated for advanced/metastatic disease.

^dOne patient did not receive an ALK TKI as their prior therapy but was included in the study.

Supplementary Table S2 All-causality AEs recorded in $\geq 5\%$ of patients by the MedDRA system organ class and preferred term

	Any grade	Grade 3	Grade 4
Any AE, <i>n</i> (%)	94 (94)	37 (37)	8 (8)
Hypertriglyceridemia	58 (58)	8 (8)	3 (3)
Hypercholesterolemia	57 (57)	3 (3)	2 (2)
Weight increased	39 (39)	12 (12)	0
Edema peripheral	29 (29)	0	0
Anemia	26 (26)	8 (8)	0
Hyperlipidemia	20 (20)	3 (3)	0
Hyperglycemia	16 (16)	2 (2)	0
Dyspnea	10 (10)	4 (4)	1 (1)
Arthralgia	9 (9)	1 (1)	0
COVID-19	9 (9)	1 (1)	1 (1)
Hypomagnesemia	8 (8)	0	0
Cough	8 (8)	0	0
Edema	7 (7)	0	0
Dyslipidemia	7 (7)	0	0
Hypertension	7 (7)	1 (1)	0
Cognitive disorder	6 (6)	2 (2)	0
Hypoalbuminemia	6 (6)	0	0
Peripheral swelling	6 (6)	0	0
Hyperamylasemia	5 (5)	0	0
Hyperkalemia	5 (5)	1	0
Pain in extremity	5 (5)	0	0

Abbreviations: AE, adverse event; MedDRA, Medical Dictionary for Regulatory Activities.